New bladder cancer trial aims to boost Body's defenses after treatment
NCT ID NCT03768570
Summary
This study is testing whether adding a drug called durvalumab after standard bladder cancer treatment helps patients stay cancer-free longer. Durvalumab is an immunotherapy that helps the body's own immune system find and fight cancer cells. The trial will enroll 82 patients who have already completed surgery, chemotherapy, and radiation to see if the extra drug improves outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Charing Cross Hospital
London, England, VV6 8RF, United Kingdom
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Health Sciences North
Greater Sudbury, Ontario, P3E 5J1, Canada
-
Hospital 12 de Octubre
Madrid, 28041, Spain
-
Hospital Clinic i Provincial
Barcelona, 08036, Spain
-
Hospital Clinico San Carlos
Madrid, 28040, Spain
-
Hospital Madrid Norte Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, 39008, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Instituto Valenciano de Oncologia
Valencia, 46009, Spain
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Nottingham University Hospitals City Hospital Campus
Nottingham, NG5 1PB, United Kingdom
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
Royal Cornwall Hospitals NHS Trust
Cornwall, England, TR1 3LQ, United Kingdom
-
Royal Devon and Exeter Hospital
Exeter, Devon, EX2 5DW, United Kingdom
-
Royal Preston Hospital
Lancashire, England, PR2 9HT, United Kingdom
-
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4, Canada
-
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, L3Y 2P9, Canada
-
The Christie NHS Foundation Trust
Manchester, England, United Kingdom
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1, Canada
-
The Royal Marsden NHS Foundation Trust - Sutton
Surrey, England, United Kingdom
-
Thunder Bay Regional Health Sciences Centre/
Thunder Bay, Ontario, P7B 6V4, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.